The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine is Highly Active in Patients (Pts) with  FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

FLT3-ITD mutation in acute myeloid leukemia (AML) is associated with early relapse and poor survival. Quizartinib inhibits FLT3 kinase activity potently and selectively. In phase I and II studies, the composite response rate was approximately 50% among pts with FLT3-ITD. There is in-vitro synergy between quizartinib and 5-azacitidine (AZA) or low dose cytarabine (LDAC). Adding quizartinib to AZA or LDAC may improve the overall response rate (ORR) and duration expected from the use of either agent alone.

Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Mahesh Swaminathan, Hagop Kantarjian, Naval Daver, Gautam Borthakur, Maro Ohanian, Tapan Kadia, Courtney DiNardo, Nitin Jain, Zeev Estrov, Alessandra Ferrajoli, Guillermo Garcia-Manero, Marina Konopleva, Michael Andreeff, Naveen Pemmaraju, Elias Jabbour, Source Type: research